Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm, multi-center, multi-national, adaptive design,
dose-escalation Phase 1/2 study to determine the maximum tolerated dose (MTD) of temsirolimus
with daily neratinib, and to determine the safety and efficacy of this combination when given
to patients with advanced breast carcinoma, specifically trastuzumab-refractory
HER2-amplified disease or triple-negative disease.